Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Sends Letter to Stockholders to Address Jerald A. Hammann's Costly, Distracting and Misguided Campaign

07/02/2021 | 10:55am EDT

The Board of Directors (the 'Board') appreciates your continued investment in Adamis Pharmaceuticals Corporation ('Adamis' or the 'Company' or 'we'). The Board also appreciates the feedback that many stockholders have provided in recent weeks. As we work to position Adamis for long-term success, please trust that this input will be carefully assessed and factored into our go-forward plans.

We are writing to you today to once again urge you to vote to re-elect all five members of the Board at the Company's upcoming Annual Meeting of Stockholders (the 'Annual Meeting') on July 16, 2021. In our view, maintaining boardroom continuity can help the Company achieve the following:

Support the ongoing Food and Drug Administration ('FDA') review of our ZIMHI New Drug Application.

Advance our Phase 2/3 trial for examining the effects of Tempol on COVID-19.

Support ongoing efforts to obtain government funding for Tempol.

Advance the Investigational New Drug for Tempol's use in radiation dermatitis.

Demonstrate a further increase in SYMJEPI sales.

Maintain a strong capital position and healthy balance sheet.

Prioritize progress across our entire product pipeline.

Based on our decades of collective experience in the biotechnology and pharmaceutical sectors, we firmly believe that Adamis is nearing a promising inflection point. We contend it is not the time to deviate from these priorities. The progress we are beginning to catalyze for SYMJEPI, ZIMHI and now Tempol stems from months and years of planning and work. This is the time to remain focused on - not pull back from - the efforts we are undertaking.

Unfortunately, Jerald A. Hammann - a holder of 1,000 shares with no industry expertise, no public company experience and no articulated plan - is trying to remove and replace 80% of your Board. We believe a more effective way for stockholders to communicate concerns is to write to the Company directly instead of seemingly throwing away a vote on Mr. Hammann's misguided effort.

We urge stockholders not to be misled for a number of reasons, including:

Mr. Hammann initially demanded a lucrative and unjusitified paid consulting agreement - which would have been paid for with stockholders' capital - before he was even a stockholder of the Company.

Mr. Hammann threatened to make books and records demands and to run a campaign against the Board if we did not quickly agree to award him the demanded consulting agreement.

Mr. Hammann has no operating experience in the biotechnology or pharmaceutical sector.

Mr. Hammann has no experience as a director or executive of a public company.

Mr. Hammann has a history of filing serial lawsuits and being a vexatious litigator.

Mr. Hammann submitted an untimely and invalid notice of director nominations. His nominations will not be accepted at the Annual Meeting.

Mr. Hammann unsuccessfully sued the Company in an attempt to delay the Annual Meeting and forced us to expend precious stockholder capital on fending off litigation.

Mr. Hammann has no plan for the Company.

We hope stockholders recognize that supporting Mr. Hammann's misguided campaign would be akin to taking what we believe is a major risk. Rather than support a litigious stockholder that is waging a costly and distracting battle with the Company, we urge you to reject his efforts by voting to re-elect your current Board.

Once again, we thank you for your investment in Adamis. We firmly believe that the Company is on the right path now that we have tangible pipeline momentum. Vote on the WHITE proxy card to elect our full five-member slate and help us sustain the Company's progress.

Sincerely,

The Adamis Board of Directors

PROTECT YOUR INVESTMENT IN ADAMIS - PLEASE SIGN, DATE AND PROMPTLY RETURN THE WHITE PROXY CARD.

The Board urges you to carefully consider the information contained in the Company's proxy materials and cast your vote on the WHITE proxy card.

DO NOT download any blue proxy card provided by Jerald A. Hammann.

DO NOT return any blue proxy card to Jerald A. Hammann even as a protest vote against his campaign.

DO NOT respond to any email or phone solicitations from Jerald A. Hammann.

CONTACT THE COMPANY'S PROXY SOLICITOR AT INFO@SARATOGAPROXY.COM OR (888) 368-0379 IF YOU HAVE ANY QUESTIONS REGARDING THE ANNUAL MEETING OR HOW TO VOTE.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc. ('USC'), compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the Company's beliefs concerning the safety and effectiveness of Tempol and the Company's other product candidates; the timing of commencement or completion of any studies or trials relating to Tempol and the availability of funding for studies or trials; the results of any studies or trials that the Company may conduct relating to Tempol; the Company's ability to successfully commercialize the products and product candidates described in this press release, itself or through commercialization partners, and the Company's beliefs concerning the commercial success of its products; future regulatory actions relating to the Company's New Drug Application ('NDA') relating to its ZIMHI product; the Company's beliefs concerning the benefits, enforceability, and extent of intellectual property protection afforded by patents and patent applications that it owns or has licensed and its rights under applicable license agreements, and its ability to enforce its patents and other intellectual property rights against third parties; the Company's expectations concerning future growth; expectations and statements about the Company's strategies, objectives, future goals and achievements; and other statements concerning our future operations, activities and financial results. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis' actual results to be materially different from the results anticipated by such forward-looking statements. There can be no assurances regarding the outcome of trials or studies relating to Tempol or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. There can be no assurances that future sales of SYMJEPI will meet our expectations. There can be no assurances regarding the timing or outcome of the FDA's review of our resubmitted NDA relating to ZIMHI, or that the Company will be able to successfully take any actions or develop any additional information that the FDA may require in connection with its review of the resubmitted NDA for ZIMHI. There can be no assurances that the FDA will consider the Company's responses included in the resubmitted NDA relating to ZIMHI as satisfactory, or that the product will be able to compete successfully in the market if approved and launched. The Company may not achieve one or more of the future goals described in the press release either within the anticipated time periods or at all. In addition, as previously disclosed, each of the Company and USC previously received a subpoena from the U.S. Attorney's Office for the Southern District of New York issued in connection with a criminal investigation. Accordingly, all forward-looking statements are subject to the outcome of this investigation, as well as the related investigation being conducted by the Company's Audit Committee. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2020 and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov.

Contact:

Saratoga Proxy Consulting

John Ferguson

E: jferguson@saratogaproxy.com

Ann Marie Mellone

T: 212-257-1311

E: amellone@saratogaproxy.com

MKA

Charlotte Kiaie

T: 646-386-0091

E: ckiaie@mkacomms.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ADAMIS PHARMACEUTICALS CORPORATION
09/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/20ADAMIS PHARMACEUTICALS CORPORATION(N : ADMP) added to S&P Global BMI Index
CI
09/13ADAMIS PHARMACEUTICALS : Departure of Directors of Certain Officers; Election of Directors..
PU
09/13ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-K)
AQ
09/13Adamis Pharmaceuticals Corporation Announces Resignation of Roshawn A. Blunt as Directo..
CI
09/02ADAMIS PHARMACEUTICALS : Begins Dosing Patients in Phase 2/3 Trial of Tempol to Treat COVI..
MT
09/02Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in t..
GL
09/02Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for..
CI
08/30NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/24ADAMIS PHARMACEUTICALS : 8-K (Form 8-K)
PU
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,18x
Yield 2021 -
Capitalization 156 M 156 M -
Capi. / Sales 2021 7,11x
Capi. / Sales 2022 15,6x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,05 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION116.45%156
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY37.51%206 972